在另一项长期癌症研究（PreSAP）中，每天服用400毫克西乐葆组的患者和安慰剂组相比没有增加心血管风险。
基于16个网页-相关网页
But Pfizer says that a second, similar study--called the PreSAP trial--does not show an increase in cardiovascular events, and that it still hopes to go forward with a study to prevent heart attacks in patients with osteoarthritis.
FORBES: Pfizer's Heart Attack
应用推荐
模块上移
模块下移
不移动